Brentuximab Vedotin

Brand names: Adcetris · Active ingredient: Brentuximab Vedotin

In short: ADCETRIS is indicated for the treatment of adult patients with previously untreated Stage III or IV cHL, in combination with doxorubicin, vinblastine, and dacarbazine. ADCETRIS is indicated for the treatment of pediatric patients 2 years and older with previously untreated high risk cHL, in combinat

Forms & strengthsFor injection: 50 mg of brentuximab vedotin as a sterile, white to off-white lyophilized, preservative-free cake or powder in a single-dose vial for reconstitution.
LabelSeagen Inc.
Label updatedNov 17, 2025

What is Brentuximab Vedotin used for?

ADCETRIS is indicated for the treatment of adult patients with previously untreated Stage III or IV cHL, in combination with doxorubicin, vinblastine, and dacarbazine.

ADCETRIS is indicated for the treatment of pediatric patients 2 years and older with previously untreated high risk cHL, in combination with doxorubicin, vincristine, etoposide, prednisone, and cyclophosphamide.

ADCETRIS is indicated for the treatment of adult patients with cHL at high risk of relapse or progression as post-autologous hematopoietic stem cell transplantation (auto-HSCT) consolidation.

ADCETRIS is indicated for the treatment of adult patients with cHL after failure of auto-HSCT or after failure of at least two prior multi-agent chemotherapy regimens in patients who are not auto-HSCT candidates.

ADCETRIS is indicated for the treatment of adult patients with previously untreated sALCL or other CD30-expressing PTCL, including angioimmunoblastic T-cell lymphoma and PTCL not otherwise specified (NOS), in combination with cyclophosphamide, doxorubicin, and prednisone.

ADCETRIS is indicated for the treatment of adult patients with sALCL after failure of at least one prior multi-agent chemotherapy regimen.

ADCETRIS is indicated for the treatment of adult patients with pcALCL or CD30-expressing MF who have received prior systemic therapy. …

âš  Boxed warning (FDA's strongest warning)

JC virus infection resulting in PML and death can occur in patients receiving ADCETRIS .

Brentuximab Vedotin dosage

The recommended ADCETRIS dosage is provided in Table 1. Administer ADCETRIS as a 30-minute intravenous infusion.

For recommended dosage for patients with renal or hepatic impairment, see

Dosage and Administration (2.2 and 2.3).

For dosing instructions of combination agents administered with ADCETRIS, see

Clinical Studies (14.1, 14.2, and 14.5) and the manufacturer’s prescribing information.

Indication | Recommended Dose

The dose for patients weighing greater than 100 kg should be calculated based on a weight of 100 kg. | Frequency and Duration

Adult patients with previously untreated Stage III or IV classical Hodgkin lymphoma | 1.2 mg/kg up to a maximum of 120 mg in combination with chemotherapy | Administer every 2 weeks until a maximum of 12 doses, disease progression, or unacceptable toxicity

Pediatric patients with previously untreated high risk classical Hodgkin lymphoma | 1.8 mg/kg up to a maximum of 180 mg in combination with chemotherapy | Administer every 3 weeks with each cycle of chemotherapy for a maximum of 5 doses

Adult patients with classical Hodgkin lymphoma consolidation | 1.8 mg/kg up to a maximum of 180 mg | Initiate ADCETRIS treatment within 4‑6 weeks post-auto-HSCT or upon recovery from auto-HSCT

Administer every 3 weeks until a maximum of 16 cycles, disease progression, or unacceptable toxicity

Adult patients with relapsed classical Hodgkin lymphoma | 1.8 mg/kg up to a maximum of 180 mg | Administer every 3 weeks until disease progression or unacceptable toxicity

Adult patients with previously untreated systemic ALCL or other CD30-expressing peripheral T-cell lymphomas | 1.8 mg/kg up to a maximum of 180 mg in combination with chemotherapy | Administer every 3 weeks with each cycle of chemotherapy for 6 to 8 doses

Adult patients with relapsed Systemic ALCL | 1.8 mg/kg up to a maximum of 180 mg | Administer every 3 weeks until disease progression or unacceptable toxicity

Adult patients with relapsed primary cutaneous ALCL or CD30-expressing mycosis fungoides | 1.8 mg/kg up to a maximum of 180 mg | Administer every 3 weeks until a maximum of 16 cycles, disease progression, or unacceptable toxicity

Adult patients with relapsed or refractory LBCL | 1.2 mg/kg up to a maximum of 120 mg in combination with lenalidomide and rituximab

Starting with cycle 2, rituximab intravenous treatment could be substituted with rituximab and hyaluronidase human via subcutaneous injection every 3 weeks. | Administer every 3 weeks until disease progression, or unacceptable toxicity

No dosage adjustment is required for mild renal impairment (CrCL greater than 50‑80 mL/min) and moderate renal impairment (CrCL 30-50 mL/min).

Avoid use in patients with severe (CrCL less than 30 mL/min) renal impairment . …

How to take Brentuximab Vedotin — instructions & advice from the label

Peripheral Neuropathy

Advise patients that ADCETRIS can cause a peripheral neuropathy. They should be advised to report to their health care provider any numbness or tingling of the hands or feet or any muscle weakness .

Fever/Neutropenia

Advise patients to contact their health care provider if a fever of 100.5°F or greater or other evidence of potential infection such as chills, cough, or pain on urination develops .

Infusion Reactions

Advise patients to contact their health care provider if they experience signs and symptoms of infusion reactions including fever, chills, rash, or breathing problems within 24 hours of infusion .

Hepatotoxicity

Advise patients to report symptoms that may indicate liver injury, including fatigue, anorexia, right upper abdominal discomfort, dark urine, or jaundice . …

Warnings & precautions

Do not take this medicine if: ADCETRIS is contraindicated with concomitant bleomycin due to pulmonary toxicity (e.g., interstitial infiltration and/or inflammation) .

ADCETRIS treatment causes a peripheral neuropathy that is predominantly sensory. Cases of peripheral motor neuropathy have also been reported. ADCETRIS-induced peripheral neuropathy is cumulative.

In studies of ADCETRIS as monotherapy, 62% of patients experienced any grade of peripheral neuropathy. The median time to onset was 3 months (range, 0–12). Of the patients who experienced neuropathy, 62% had complete resolution, 24% had partial improvement, and 14% had no improvement at their last evaluation. The median time from onset to resolution or improvement was 5 months (range, 0–45). Of the patients with ongoing neuropathy (38%), 71% had Grade 1, 24% had Grade 2, and 4% had Grade 3.

In ECHELON-1 (Study 5), 67% of patients treated with ADCETRIS + AVD experienced any grade of peripheral neuropathy. The median time to onset of any grade was 2 months (range, 0–7), of Grade 2 was 3 months (range, 0–6) and of Grade 3 was 4 months (range, <1–7). By the time of the primary analysis, 43% of affected patients had complete resolution, 24% had partial improvement, and 33% had no improvement at their last evaluation. The median time from onset to resolution or improvement of any grade was 2 months (range, 0–32).

At the updated analysis of ECHELON-1, 72% of the patients who experienced peripheral neuropathy had complete resolution, 14% had partial improvement, and 14% had no improvement. The median time to partial improvement was 2.9 months (range, <1–50), and the median time to complete resolution was 6.6 months (range, <1–67). Of the patients with ongoing neuropathy (28%), 57% had Grade 1, 30% had Grade 2, 12% had Grade 3, and <1% had Grade 4. …

Brentuximab Vedotin side effects

The following clinically significant adverse reactions are described elsewhere in the labeling:

•Peripheral Neuropathy

•Anaphylaxis and Infusion Reactions

•Hematologic Toxicities

•Serious Infections and Opportunistic Infections

•Tumor Lysis Syndrome

oIncreased Toxicity in the Presence of Severe Renal Impairment

•Increased Toxicity in the Presence of Moderate or Severe Hepatic Impairment

•Hepatotoxicity

•Progressive Multifocal Leukoencephalopathy

•Pulmonary Toxicity

•Serious Dermatologic Reactions

•Gastrointestinal Complications

•Hyperglycemia

Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.

The data below reflect exposure to ADCETRIS in 931 adult patients with cHL including 662 patients who received ADCETRIS in combination with chemotherapy in a randomized controlled trial, 269 who received ADCETRIS as monotherapy (167 in a randomized controlled trial and 102 in a single arm trial), and 296 pediatric patients with high risk cHL who received ADCETRIS in combination with chemotherapy. …

Drug interactions

CYP3A4 Inhibitors: Co-administration of ADCETRIS with ketoconazole, a potent CYP3A4 inhibitor, increased exposure to MMAE , which may increase the risk of adverse reaction. Closely monitor adverse reactions when ADCETRIS is given concomitantly with strong CYP3A4 inhibitors.

About this medicine

ADCETRIS (brentuximab vedotin) is a CD30-directed antibody and microtubule inhibitor conjugate consisting of three components: 1) the chimeric IgG1 antibody cAC10, specific for human CD30, 2) the microtubule disrupting agent MMAE, and 3) a protease-cleavable linker that covalently attaches MMAE to cAC10.

Brentuximab vedotin has an approximate molecular weight of 153 kDa. Approximately 4 molecules of MMAE are attached to each antibody molecule. Brentuximab vedotin is produced by chemical conjugation of the antibody and small molecule components. The antibody is produced by mammalian (Chinese hamster ovary) cells, and the small molecule components are produced by chemical synthesis.

ADCETRIS (brentuximab vedotin) for injection is supplied as a sterile, white to off-white, preservative-free lyophilized cake or powder in single-dose vials. Following reconstitution with 10.5 mL Sterile Water for Injection, USP, a solution containing 5 mg/mL brentuximab vedotin is produced. …

Disclaimer: This page is for general information only and is not medical advice. It is a condensed summary of the official FDA-approved label — it does not replace the full prescribing information or the advice of your doctor or pharmacist. Always follow your prescriber's instructions and read the medication guide that comes with your medicine.

Source: FDA-approved label via DailyMed (U.S. National Library of Medicine), label set ID 3904f8dd-1aef-3490-e48f-bd55f32ed67f. Read the full official label on DailyMed.

Related medicines

Levothyroxine Allopurinol Ondansetron Finasteride Clonidine Testosterone Thyroid Methotrexate